Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The aim of this study is to evaluate the effect of different antihypertensive drugs in women with pregnancy hypertension on maternal and fetal/neonatal outcomes.

Giant Panda

ABOUT THE STUDY

 The primary objective is to evaluate if treatment with nifedipine (calcium channel blocker), compared to labetalol (mixed alpha/beta blocker) in women with pregnancy hypertension, reduces severe maternal hypertension without increasing fetal or neonate adverse events.

 

WHO CAN PARTICIPATE IN THIS STUDY? 

Inclusion criteria

11+0 – 34+6 weeks

Diagnosis of pregnancy hypertension (Chronic/gestational or Pre-eclampsia)

>18 years old

Clinicians’ decision to initiate antihypertensive drugs

 

Exclusion criteria

Contraindication to either Labetalol or Nifedipine

Already taking both medications.

 

What to expect

  • You will be randomly assigned to receive one of two drugs Nifedipine or Labetalol. Both of these medications for blood pressure are usual clinical practice.
  • Observational: Data input only (for the women who are eligible but excluded due to contraindication to either medication or women already taking both antihypertensive drugs)
  • Post randomisation contact – safety check after 2 weeks
  • Post randomisation contact – after 6 weeks (4 weekly thereafter)

 

For further information, please read our study leaflet.

 

HOW CAN I GET INVOLVED?

Giant Panda Research Team

Nuffield Department of Women’s and Reproductive Health, University of Oxford

The Women’s Centre, John Radcliffe Hospital

Oxford

OX3 9DU

Phone: 01865 221107/07925148248

Email: OSPREA@wrh.ox.ac.uk

 

Ethical Approval

This study has been ethically approved by the London - South East Research Ethics Committee.

REC number: 20/LO/1110